Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)
Condition(s):Esophageal Squamous Cell CarcinomaLast Updated:July 13, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Esophageal Squamous Cell CarcinomaLast Updated:July 13, 2023Recruiting
Condition(s):Urothelial CarcinomaLast Updated:January 24, 2024Recruiting
Condition(s):HER2-positive Breast CancerLast Updated:September 30, 2022Not yet recruiting
Condition(s):Locally Advanced Rectal CancerLast Updated:April 6, 2023Not yet recruiting
Condition(s):Breast Cancer; HER2-positive Breast CancerLast Updated:February 26, 2024Not yet recruiting
Condition(s):Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical ProstatectomyLast Updated:January 13, 2022Recruiting
Condition(s):HER2 Negative Breast CancerLast Updated:November 4, 2016Completed
Condition(s):Inflammatory Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of BreastLast Updated:February 6, 2024Active, not recruiting
Condition(s):Desmoplastic MelanomaLast Updated:November 29, 2023Active, not recruiting
Condition(s):Non Small Cell Lung CancerLast Updated:July 29, 2022Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.